Heart Test Laboratories, Inc. (HSCS)
NASDAQ: HSCS · IEX Real-Time Price · USD
0.0945
+0.0019 (2.05%)
At close: May 2, 2024, 4:00 PM
0.0920
-0.0025 (-2.65%)
After-hours: May 2, 2024, 7:44 PM EDT
Heart Test Laboratories Revenue
Heart Test Laboratories had revenue of $18.60K in the twelve months ending January 31, 2024, with 100.02% growth year-over-year. Revenue in the quarter ending January 31, 2024 was $14.70K with 653.85% year-over-year growth. In the fiscal year ending April 30, 2023, Heart Test Laboratories had annual revenue of $5.15K, a decrease of -64.17%.
Revenue (ttm)
$18.60K
Revenue Growth
+100.02%
P/S Ratio
327.81
Revenue / Employee
$1,550
Employees
12
Market Cap
6.20M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Apr 30, 2023 | 5.15K | -9.22K | -64.17% |
Apr 30, 2022 | 14.37K | -11.23K | -43.86% |
Apr 30, 2021 | 25.60K | -38.58K | -60.11% |
Apr 30, 2020 | 64.18K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionHSCS News
- 8 days ago - HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG - GlobeNewsWire
- 4 weeks ago - HeartSciences to Present at the LD Micro Invitational XIV Conference - GlobeNewsWire
- 5 weeks ago - HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients - GlobeNewsWire
- 7 weeks ago - HeartSciences Reports Third Quarter Fiscal 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes - GlobeNewsWire
- 2 months ago - HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology - GlobeNewsWire
- 2 months ago - HeartSciences Adds Key Advisor to its Scientific Advisory Board - GlobeNewsWire
- 2 months ago - HeartSciences Expands its Scientific Advisory Board - GlobeNewsWire